Sinobiomed (SOBM) is a Chinese developer of genetically engineered recombinant protein drugs and vaccines. The company’s drugs treat diseases and ailments such as malaria, hepatitis, surgical bleeding, cancer, rheumatoid arthritis, diabetic ulcers and burns, and blood cell regeneration. Sinobiomed currently has 10 products: three on the market, four in clinical trials and three in research and development.

Sinobiomed, based in the bustling metropolis of Shanghai, could be on the forefront of the burgeoning Chinese biotechnology industry. China’s biotech industry is expected to continue its rapid expansion of 20 percent to 30 percent annually to $8.5 billion by 2010 helped by government contributions of $600 million annually. The Chinese pharmaceutical industry is expected to be the world’s 5th largest market by 2010.

Sinobiomed is considered a market leader in the area of recombinant protein drugs and recently acquired a distributor to facilitate a more expeditious sale of some its drugs. The

Sinobiomed Inc. (SOBM.OB) is a leading Chinese developer of genetically engineered recombinant protein drugs and vaccines. Sinobiomed employs a patented low-cost, high yield production process to enhance bioactivity and guarantee the highest levels of purity.

Sinobiomed currently has 10 products approved or in development: three on the market, four in clinical trials, and three in R&D. The company’s products respond to a wide range of diseases and conditions, including: hepatitus B&C, surgical bleeding, diabetic ulcers and burns, malaria, cancer, rheumatoid arthritis, acute liver disease, stroke, blood clots and thrombosis, acute pancreatitis, and blood cell regeneration.

Sinobiomed has several competitive advantages in addition to the company’s patented recombinant protein manufacturing process. One advantage is the company’s strong strategic alliances with leading Chinese research hospitals and institutes for collaborative development of patentable techniques and treatments. Another advantage is the company’s distribution network.

Sinobiomed has also established a nationwide sales and marketing network along with international

Sinobiomed’s (OTCBB: SOBM) recombinant Batroxobin (rBAT) is in its Phase IIb trials for 328 patients. Results are expected before year’s end. A company news release says international interest from government and organizations would grow significantly if the product proceeds to Phase III clinical trials.

“[We have] already received indications of interest from global pharmaceutical companies for joint development, marketing and production,” the release states.

Clinical trials for Sinobiomed’s recombinant malaria candidate vaccine are set to begin before the end of the 3rd Quarter. The tests are tentatively planned to take place at Mahidol University in Bangkok, Thailand.

Batroxobin is produced through genetic engineering of the venom, which reduces the risk of biological contaminates associated with natively extracted batroxobin.

Sinobiomed also has majority ownership in a skincare and cosmetics line, through Shanghai Wanxing Bioscience Cosmetics. Sales of more than $3 million over the coming year are expected, with anticipated gross profit margins greater than 70